Virginiamycin Market Moving Toward 2026 With New Procedures

Virginiamycin Market Moving Toward 2026 With
New Procedures
Virginiamycin Market, by Animal (Poultry, Cattle, Swine, Horse, and Others), by
Application (Necrotic Enteritis, Coccidiosis, Growth Stimulation, and Feed
Additive For Cattle And Poultry), by Distribution Channel (Veterinary Hospital
Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size,
Share, Outlook, and Opportunity Analysis, 2019–2026
Virginiamycin is an antibiotic produced by Streptomyces virginiae and belongs to the streptogramin
group, which has two synergistic factors: M (hybrid polyketide-peptide) and S (peptide). It is used in
the fuel ethanol industry to prevent microbial contamination. Virginiamycin is an antibiotic, which was
marketed for vancomycin resistant enterococcus in the U.S. in 1999. It is also used in the agriculture
sector specifically in livestock to accelerate the growth of animals and prevent and treat infections.
Virginiamycin is a mixture of two principle components of virginiamycin M1 and virginiamycin S1.
Virginiamycin controls microbial growth within lumen of gastrointestinal tract by disrupting bacterial
protein synthesis. Click To Read More On Virginiamycin Market.
Virginiamycin can also be used as a growth stimulator as it optimizes the absorption and metabolism of
nutrients. It also improves the state of small intestine epithelium and inhibits the growth of harmful
toxins and metabolites by gut organisms. Virginiamycin is used for the treatment of necrotic enteritis in
broiler chickens — a common fatal gastrointestinal disease in poultry.
Virginiamycin Market- Dynamics
Pharmaceutical manufacturers are focused launching new products to address limited availability of
Virginiamycin and to enhance their market share. This in turn is expected to augment the market
growth. For instance, in January 2019, Phibro Animal Health Corp. announced that its virginiamycin
medicated feed additive received regulatory approval by Veterinary Drugs Directorate (VDD), Health
Canada, for use in beef cattle. According to Phibro Animal Health Corp., V-max (virginiamycin) is
approved for the reduction of incidence of liver abscesses in cattle fed in confinement.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2621
In developing countries there is rapid increase of demand for livestock. In developed countries, demand
for livestock is stagnating. Increasing demand for livestock due to growing human population is
expected to boost growth of the market. Increasing livestock production leads to high demand for
animal feed.
Stringent regulations by the regulatory agencies is expected to hinder market growth. In September
2015, the European Commission adopted the regulation establishing maximum residue limits for
virginiamycin in poultry species, which is valid throughout the European Union.
Virginiamycin Market- Competitive Analysis
Key players in the market are focused on development, manufacturing, and marketing of multisource
and branded pharmaceuticals, thereby augmenting the market growth. For instance, in January 2017,
Huvepharma AD received approval for STAFAC (virginiamycin) plus CLINACOX (diclazuril)
combination drug type in chickens for prevention of necrotic enteritis and coccidiosis in broiler
chickens.
Key players operating in the global virginiamycin market include, Hongcong Xinrunde Chemical Co.,
Ltd, Xiamen ShengLang SaiChuang Biological Technology Co., Ltd., Manus Aktteva Biopharma,
Alfanzyme, Phibro Animal Health Corporation, Merck Animal Health, Zoetis, Elanco, Virbac, Ceva,
and Vetoquinol.
Virginiamycin Market- Market Taxonomy
On the basis of animal, the global virginiamycin market is segmented into:
•Poultry
•Cattle
•Swine
•Horse
•Others
On the basis of application, the global virginiamycin market is segmented into:
•Necrotic enteritis
•Coccidiosis
•Growth Stimulation
•Feed Additive for Cattle and Poultry
On the basis of distribution channel, the global virginiamycin market is segmented into:
•Hospital Pharmacies
•Retail Pharmacies
•Online Pharmacies
Virginiamycin Market- Regional Dynamics
On the basis of region, the global virginiamycin market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. The rapid increase in livestock animals is the
main reason for North America region to hold a dominant position in the global virginiamycin market
over the forecast period in terms of revenue share followed by Europe. The virginiamycin market in
this region has been growing due to the necessity for the additional supplements in the diet for a
companion as well as livestock animals for appropriate nutrition. The consumption of virginiamycin is
high in Europe, which is expected to drive the virginiamycin market growth in the region. For instance,
in January 2017, virginiamycin was approved for use in feed. Upon completion of voluntary conversion
from over the counter to veterinary feed directive(VFD), all feed uses of the virginiamycin alone or in a
combination, will require the VFD. The proprietary drug names of virginiamycin is Stafac and V-max.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Virginiamycin can also be used as a growth stimulator as it optimizes the absorption and metabolism of nutrients. It also improves the state of small intestine epithelium and inhibits the growth of harmful toxins and metabolites by gut organisms.

Download Report